Tag Archives: payers

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 1 Comment

Drug-Diagnostic Development Stymied by Payer Concerns

The shift to personalized medicine, which supports medical treatment tailored to individual patient characteristics, has been hindered by uncertainty over the value, accuracy and clinical utility of companion diagnostic tests. Even for the handful of drugs approved by the Food and Drug Administration with labeling that links prescribing to specific biomarker measures, health plan operators, […]
Posted in FDA, Gene therapy, Legal, Market Access, R&D, Regulatory, Technology | Also tagged , , , , , , , , | Leave a comment

For Becton Dickinson, Medication Errors are a Business Opportunity

Over the next few years, med tech company Becton Dickinson will launch up to 30 generic, pre-filled syringes in an attempt to lower medication errors and raise company revenues, according to BD Rx president Mark Sebree. One man’s goof is another man’s growth, potentially.
Posted in FDA, Manufacturing, pricing, R&D, Safety, Strategy, Technology | Also tagged , , , , | Leave a comment

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, leadership, Market Access, pricing, R&D, Strategy | Also tagged , , , | Leave a comment

Fixing Biotech's Broken Business Model

Despite some notable successes, the global biotech industry has fallen short of expectations. Strategic collaborations have been on the increase, but there is now a need for more co-operation using new collaboration models, writes Jo Pisani. The current business model on which biotech has relied is flawed. Due to poor rates of return, investment has […]
Posted in Biotech, Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta